Authors' recommendations: There was no evidence to assess the relative efficacy and safety of Genotropin versus other somatropin products available in Canada for the treatment of adults with GHD. While all somatropin products have the same amino acid sequence as endogenous human GH and similar pharmacokinetic profiles, they differ somewhat with respect to manufacturing processes, dosage forms, excipients, dosing recommendations, and approved indications. Systematic reviews of somatropin products for the treatment of adult GHD indicate possible improvements in some dimensions of HRQoL, exercise performance, lipid profile, and body composition compared with placebo or no treatment, although results were inconsistent across studies for some outcomes, and the clinical importance of the observed changes is uncertain. The only consistent benefit of Genotropin in the manufacturer-submitted placebo-controlled RCTs was improved body composition, but, once again, the effects were of uncertain clinical significance.

Project Status: Completed

Year Published: 2014

URL for published report: http://www.cadth.ca/media/cdr/clinical/SR0332_GenotropinGHD-A_CL_Report_e.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)